Alternative approaches to developing strategic partnerships in order to drive discovery and innovation and enhance pipelines. http://www.globaldiscoverycollaborations.com

1. Register and pay before 30th July and save up to £400
GLOBAL DISCOVERY
OUTSOURCING AND
COLLABORATIONS
FORUM 2010
Two Day Conference: 20th – 21st October 2010
Pre-Conference Workshop Day: 19th October
CCT Venues, Canary Wharf, London, UK
Hear from 17 leading pharma
Alternative approaches to developing and bio experts…
www.globaldiscoverycollaborations.com
Frederik Deroose,Director, Head External
strategic partnerships: driving discovery, Collaborations and Outsourcing Services,
Johnson & Johnson
innovation and enhancing pipelines Michael Sierra, Director of External Discovery,
Leo Pharma
Dr Iain Comley, Associate Director,
Key reasons to attend: Science & Technology Alliances,
AstraZeneca
® aximise profitability through strategic and tactical partnerships and examine
M
Dr Stephen Shuttleworth, CSO,
a range of partner selection processes with GlaxoSmithKline, Novartis Karus Therapeutics
and Merck Dr Zoran Rankovic, Associate Director,
Medicinal Chemistry,
Investigate the varying scales of partnerships in emerging markets and
®
Merck UK
assess long term strategies for working in Asia with discussions from AstraZeneca Pascal Touchon, Director,
Facilitate access to innovative technologies and high level expertise:
®
Head of Scientific Collaboration
& Business Development,
where is there room for innovation in your business model? Case studies Servier
and discussions from Nycomed and Symphogen Patrice Talaga, Director Chemistry Outsourcing,
Establish early alliance and risk sharing collaborations and examine the
®
UCB
Mathias Schmidt, Associate Principal,
licensing considerations with the latest developments from Bristol-Myers Head of Early Alliance Team,
Squibb and UCB. Get the Nycomed
academic’s perspective from Imperial College London Drug Discovery Unit Hansjoerg Lehmann, Lab Head,
Preparation Laboratories,
® iscuss the most effective outsourcing and collaboration strategies to
D
Novartis
ensure your partner meets the needs of your company and drives the pipeline Jorge Beleta, Director Discovery Strategy,
forward. Hear the latest strategies from Novartis, Novo Nordisk and Leo Pharma Almirall
Promote growth and innovation through implementing a virtual Pharma
®
Dr Catherine Tralau, Head of Drug Discovery
Facility& Pharmacology,
model with case studies from Poxel and Karus Therapeutics. Imperial College London
Jayshree Mistry, Outsourcing Associate,
GlaxoSmithKline
Pre-Conference Workshop Day Lubor Gaal, Head of Europe,
Plus an interactive preconference workshop day addressing the set up and Strategic Transactions Group,
management of early alliances, key strategies for effective relationship management. Bristol Myers-Squibb
Hear case studies from Novartis, GlaxoSmithKline and Merck Søren Bregenholt, COO and Head Preclinical R&D,
Symphogen
Sophie Hallakou-Bozec,
Research Director and Cofounder,
Poxel
Johan Weigelt,
Zoran Rankovic, Mathias Schmidt, Hansjeorg Lehmann, Chief Scientist,
Associate Director Associate Principal, Lab Head, Structural Genomics Consortium
Medicinal Chemistry, Head Early Alliance Team, Preparation Laboratories, Tomas Landh,
Merck UK Nycomed Novartis Director of Strategy and Sourcing,
Novo Nordisk
Telephone: Fax: Email: Visit:
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com

2. SPONSORS AND EXHIBITORS
Who will attend?
Directors, senior managers and managers
within pharmaceutical manufacturers, biotech
companies and academic institutes with
responsibility for:
• Discovery Outsourcing • Business Development
• R&D • Chemistry
• Externalisation • Alliances
• Discovery Strategy • Strategic Partnerships
Why Attend?
Explore the varying scales of partnerships
and business models to drive innovation,
access the latest expertise and technologies
and enhance pipelines.
Maximise Your Involvement:
Sponsorship and Exhibition
Opportunities About Pharma IQ
The Pharma IQ Global Discovery Outsourcing and Collaborations Forum Web: www.pharma-iq.com Phone: +44 (0) 207 368 9300
will be the perfect platform for service providers to meet senior-level Become a member of Pharma IQ and receive complimentary access to
decision makers in the pharmaceutical/biopharmaceutical industry resources that will keep you at the forefront of industry change. You will
implementing specific drug discovery solutions and services. receive access to our growing library of multi-media presentations from
Contact Pharma IQ to discuss how to position your company in front to industry leaders, an email newsletter updating you on new content that
your participants who are keen to learn more about today’s technologies has been added, free aggregated news feed from over 1000 global news
and services including: Leo Pharma, Almirall, Nycomed, UCB, Bristol sources tracking your industry and special member only discounts
Myers-Squibb and many more. on events. Become a member here: www.pharmaceuticaliq.com/
‘Very valuable, learned a lot, inspired.’ Novartis Pharma
Media Partners:
Telephone: Fax: Email: Visit:
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com

3. Pre-Conference Workshop Day. Tuesday 19th October 2010
Examining Various Business Models to Achieve the
Optimum Partnership and Maximise Profitability
10.30 – 13.30
WORKSHOP A:
Enhancing Efficiency and Productivity in Lead Discovery
This interactive workshop will give attendees the platform to discuss lead discovery and optimisation process, as well as the
outsourcing considerations during these processes to ensure efficiency and profitability.
You will walk away from this workshop with new ideas on:
• Understanding the hit to lead process in the context of drug discovery
• What to outsource and how to find a suitable CRO/partner
• Effective hit generation strategies
• Hit selection – defining the selection criteria and decision making process
• Hit optimisation; assessing risks and addressing deficiencies
• Medicinal chemistry strategies and tips to improve hERG selectivity and ADME properties
Facilitator: Dr Zoran Rankovic, Associate Director, Medicinal Chemistry, Merck UK
14.30 – 17.30
WORKSHOP B:
Setting Up and Effectively Managing Early Alliances
By attending this hands on workshop attendees will gain in depth insights into the practical approaches of setting up early
alliances and strategies to maximise internal and external resources in a bid to drive discovery.
In this workshop you will walk away with new initiatives on:
• How to implement an early alliance effectively
• An overview of the internal and external opportunities
• Interacting with your partner to understand expectations and ensure a successful partnership
• Case studies
Facilitator: Mathias Schmidt, Associate Principal, Head of Early Alliance Team, Nycomed
OR
14.30 – 17.30
WORKSHOP C:
Achieving an Effective Working Relationship with your Partner
to Ensure a Successful a Profitable Collaboration
This hands on workshop will enable participants to understand the long term considerations of a collaboration and solutions to
effectively manage expectations and ensure a successful partnership
From this workshop attendees will gain a fresh perspective on:
• Ensuring reliability of quality and timing from your partner
• Assessing the long-term benefits of an winning partnership, not just the short-term cost savings
• Establishing flexibility regarding reporting and communications with providers from emerging markets
Facilitator: Hansjoerg Lehmann, Lab Head, Preparation Laboratories, Novartis
‘Great mix of presenters covering a comprehensive range
of topics-well done. Superb networking opportunity.’ Pfizer
Telephone: Fax: Email: Visit:
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com

4. Conference Day One. Wednesday 20th October 2010
08.15 Registration and Coffee 12.40 Early Alliances and Risk Sharing Portfolios: An Academic’s
Perspective
08.50 Pharma IQ’s Welcome and Opening Remarks from Chairperson CASE • The growth of robust drug discovery models within academia
Pascal Touchon, STUDY
Director, Head of Scientific Collaboration • The academic virtual biotech model within Imperial and why it is such an efficient option
& Business Development, Servier • The importance of early phase collaborations to deliver pharma’s future pipeline
• Challenging the traditional Pharma drug discovery model
Dr Catherine Tralau,
Understanding the Varying Scales of Partnerships Head of Drug Discovery Facility & Pharmacology,
and Collaborations and Implementing the Right Imperial College London
Business Model to Suit Your Needs
13.20 Networking Lunch
09.00 Optimising Your Business Model: Outsourcing vs. Collaboration 14.50 Breakout Roundtable Discussions
• Assessing the spectrum of collaboration with external partners to enhance access
to scientific and technological resources Participants will be able to choose one of the roundtables outlined below and
• Saving time and cost through outsourcing combined processes spend 45 minutes discussing the points before feeding back to the group.
• Maximising external resources by implementing varying partnership models
• Identifying potential partners and understanding the differences when working Roundtable A:
with a private company and with academia CASE
• Where is there room for innovation in your business model? STUDY Global Licensing Strategies
Tomas Landh, • Assessing the opportunities and establishing strategic deals to drive innovation
Director Strategy and Sourcing, • Identifying new licensing prospects that will close gaps in therapeutic areas
Novo Nordisk • Case studies and experiences of effective licensing partnerships
Lubor Gaal,
09.40 Sharing Intellectual Property and Working in Intellectual Head of Europe, Strategic Transactions Group,
Tandem to Improve Innovation and Drug Development Bristol Myers-Squibb
• Choosing the scale of input from your partner and structuring the agreements
accordingly
• An overview of licensing options and ensuring the a mutually beneficial deal Roundtable B:
• Establishing IP ownership deals that provide mutual benefit CASE Risk Sharing Partnerships: Understanding the Long
• Combining problem solving and intellectual sharing with external partners to drive STUDY Term Value
drug discovery and speed time to market • Exploring the degrees of collaboration with CROs: what can your CRO offer you
Soren Bregenholt, in terms of intellectual input?
COO,
Jorge Beleta,
Symphogen
Director Discovery Strategy,
Almirall
10.20 CRO SPOTLIGHT SESSION 15.30 Public Private Partnerships – A Working Model for Open
This session will be dedicated to a leading service provider within the drug Innovation
discovery field, offering you the opportunity to hear first hand how the latest CASE • An overview of collaborative models
innovations can help you reach your drug development goals. STUDY
• The pre-competitive boundary
• Protein family based chemical biology
• Tools for target validation
10.50 Networking Coffee Break
Johan Weigelt,
11.20 Open Innovation and Risk Sharing Partnerships – Chief Scientist,
What are the Benefits and Practicalities? Structural Genomics Consortium
CASE
STUDY • An overview of open innovation and the set up practicalities
• Finding new, innovative models to replenish the pipeline 16.10 Networking Refreshment Break
• Operational excellence and open innovation: are they compatible?
• Successful Open Innovation: what matters?
Patrice Talaga, Implementing Varying Licensing Partnerships to
Director Chemistry Outsourcing, Fill IP Gaps
UCB
12.00 Driving Innovation through Early Alliances and Understanding 16.40 Clarifying the Contractual and Legal Landscapes of
the Practical and Relationship Management Implications Early Alliances
CASE • Case studies and experiences of effective licensing partnerships
• Brief overview about the standing of biologics in the pharma industry – why can STUDY
pharma NOT afford to neglect biologics • An overview of various types of partnerships in early stages of drug discovery
• Implementing a biologics strategy into a pharma company with a traditional focus • Moving from strategic research alliance to licensing
on small molecule drugs rather than biologics • Key issues linked with partners capabilities
• Expanding the biologics portfolio through forming early alliances – a win-win • Managing the IP portfolio over the long term
situation that circumvents the implementation of complicated and sophisticated • Building the right foundations for long term partnership in the contract
technology platforms in-house Pascal Touchon,
• Assessing the needs and motivations of your partner and the importance of Director, Head of Scientific Collaboration
matching them with your own & Business Development, Servier
Mathias Schmidt,
Associate Principal, Head of Early Alliance Team,
Nycomed 17.20 Closing Remarks from Chairperson and End of Day Two
Telephone: Fax: Email: Visit:
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com

5. Conference Day Two. Thursday 21st October 2010
08.15 Registration and Coffee 12.10 Effectively Matching Your Requirements to CRO Capabilities
09.00 Pharma IQ’s Welcome and Opening Remarks from Chairperson to Drive Productivity and Enhance Value
Sophie Hallakou-Bozec, • An overview of the what can be outsourced during the discovery process
Research Director and Cofounder, • Improving value and cost-effectiveness through prioritising your outsourcing
Poxel • Outsourcing part or all of the discovery process: what are the benefits and
considerations?
Maximising Partnership Productivity Through • Matching the capabilities of CROs to your specific needs to ensure access
Effective Identification, Selection and Relationship to high quality expertise and technologies
Michael Sierra,
Management Director of External Discovery,
09.10 Successfully Driving Drug Discovery and Development Leo Pharma
CASE
through Establishing a Virtual Pharmaceutical Model
STUDY • Rationale for a virtual R&D model 12.50 Networking Lunch
• Key criteria to assess and collaborate with potential partners
• Implementation and management of the partnership: leveraging the success 14.20 Ensuring a High Return on Investment for All Discovery
of the collaboration Partnerships
• Maximising profitability and productivity throughout the discovery and • Understanding the variability of outsourcing quality for different processes
development process • Tracking the cumulative costs of outsourcing as a whole to determine the overall
Sophie Hallakou-Bozec, costs and ROI
Research Director and Cofounder, • Assessing your internal resources to make tactical partnering decisions
Poxel • Getting value for money at all service levels
09.50 Targeted Small Molecule Lead Discovery, Optimisation • Negotiation strategies to ensure a fair deal at the earliest stage
Frederik Deroose,
and Development in a Semi-Virtual R&D Environment
CASE Director, Head External Collaborations
STUDY
• Creating and developing a unique scientific angle, building the right internal team
and Outsourcing Services, Johnson & Johnson
of experimentalists, identifying CROs with specific strengths in the lead discovery,
development and optimisation process
• Establishing the right balance between internally-conducted versus externally- Driving Efficiency and Cost Reductions through
sourced chemistry and in vitro and in vivo biology, pharmacology and toxicology
• Identifying key academic collaborators on translational research
Strategic Outsourcing to Emerging Markets
• Case histories outlining the discovery and development of novel PI3K-p110beta/
delta dual inhibitors for the treatment of immune-inflammatory diseases, and
15.00 Outsourcing in Discovery Chemistry: Strategy, Selection, Success
• Identifying your needs to establishing a suitable business model
on HDAC6-selective inhibitors for the treatment of inflammation, cancer and CASE • Selection process: identifying the optimum business partner (CRO)
neurodenegeration Y
STUD • Improving and fostering an efficient collaboration
Dr Stephen Shuttleworth,
• Successfully managing outsourcing projects
CSO,
• Effective approaches to troubleshooting
Karus Therapeutics
• Monitoring of key success determinants
Hansjoerg Lehmann,
10.30 Networking Refreshment Break
Lab Head, Preparation Laboratories,
11.00 Interactive Cross Sector Panel: Novartis
Early Alliance Partnerships Between Academia and Pharma
• Pharma’s strive for operational excellence and examples of breakthroughs type 15.40 Networking Refreshment Break
of research collaborations
• Common misperceptions from academia: aligning scientific mechanisms and Practical Approaches to Virtual Pharma: Ensure
medical utilities and the need to match the expectations of all partners
• Common misperceptions in pharma: working together to develop underlying
Success through Efficient Set Up and Management
science and valuable therapeutics of Partnerships
• THE SOLUTION – Trying to Speak the Same Language: Creating a common
understanding of both, academia’s and pharma’s capabilities and capacities 16.10 Outsourcing Chemistry: Finding the Right Partner for the
• Funding options to facilitate early industry-academic collaborations and deliver CASE Right Job
the required industry outcome STUDY • Data sets for the transition from preclinical to clinical testing
Dr Catherine Tralau, Head of Drug Discovery Facility & Pharmacology, • What and where to outsource
Imperial College London • Choosing the right partner and most suitable business model
Patrice Talaga, Director Chemistry Outsourcing, UCB • Managing collaboration and key performance indicators
Mathias Schmidt, Associate Principal, Head of Early Alliance Team, Nycomed • Case studies
Dr Zoran Rankovic,
Understanding the Real Cost of Outsourcing and Associate Director, Medicinal Chemistry,
Merck UK
Ensuring Value throughout the Whole Discovery Process
11.30 Creating Collaborative and Risk Sharing Partnerships in 09.10 Establishing Optimum Selection Criteria to Enhance the CRO
Emerging Markets Selection Process
• The advancement of business models available in the Asian market with the • Identifying your needs and applying an appropriate business model to get the
move from traditional outsourcing to collaborations and risk sharing most out of your partners
• Taking an alternative approach to partnering with CROs in Asia and gaining access • Assessing the track record and capabilities of CROs
to high quality technology and expertise • Implementing pilot studies to directly assess several partners simultaneously
• Obtaining insight into the levels of training and scientific knowledge outside and taking a comparative approach
Western Europe as a key decider in the type of partnership • Using internal expertise to interpret quality of pilot study data and assess consistency
• Understanding cultural differences and establishing effective communication Jayshree Mistry,
to ensure a successful collaboration Outsourcing Associate,
Dr Iain Comley, GlaxoSmithKline
Associate Director,
Science & Technology Alliances, AstraZeneca 17.20 Closing Remarks from Chairperson and End of Day One
Telephone: Fax: Email: Visit:
+44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com

6. GLOBAL DISCOVERY OUTSOURCING 5 easy ways to register
AND COLLABORATIONS
Web www.globaldiscoverycollaborations.com
FORUM 2010
Two Day Conference: 20th – 21st October 2010 Phone +44 (0) 20 7368 9300
Pre-Conference Workshop Day: 19th October
CCT Venues, Canary Wharf, London, UK Fax +44 (0) 20 7368 9301
REGISTRATION FORM
To speed registration, please provide the priority code located on the mailing label or in the box below.
Email enquire@iqpc.co.uk
My registration code is PDFW Post IQPC Ltd. Anchor House,
Please contact our database manager on +44(0) 207 368 9300 or at database@iqpc.co.uk quoting the
registration code above to inform us of any changes or to remove your details.
15-19 Britten Street,
London SW3 3QL
TEAM DISCOUNTS
IQPC recognises the value of learning in teams. Groups of 3 or more
booking at the same time from the same company receive a 10%
discount. 5 or more receive a 15% discount. 7 receive a 20% discount.
Only one discount available per person. Team discounts are not
applicable in conjunction with another discount.
Delegate Rates
FREE ONLINE RESOURCE
Our website has changed! You will now find a variety of resources
Book and Pay Book and Pay
Package Before 30th July*** Before 3rd September***
Standard Price such as articles, news, podcasts and presentations available online.
Many of these features are exclusive to IQPC so visit
www.globaldiscoverycollaborations.com today and learn something
Conference + 2 Workshops ** Save £400 Save £300 new for free.
+ Full access to
c £2596 + VAT c £2696 + VAT c £2996 + VAT
Conference Recordings *
Conference
+ Two Workshops **
Save £300
c £2197 + VAT
Save £200
c £2297 + VAT c £2497 + VAT VENUE INFORMATION
Venue: CCT Venues – Canary Wharf, Isis Building, Thames quay, 193
Marsh Wall, London, E14 9SG
Conference + 1 Workshop ** Save £300 Save £200 Tel: +44 (0)20 7332 0881 Fax. +44 020 7332 0882
+ Full access to conference
c £2197 + VAT c £2297 + VAT c £2497 + VAT Email: enquire@cctvenues.co.uk
recordings *
ACCOMMODATION:
Conference + 1 Workshop ** Save £200 Save £100 Hotel accommodation is not included in the conference fee.
c £1798 + VAT c £1898 + VAT c £1998 + VAT To view accommodation nearby please visit
www.cctvenues.co.uk/cw_hotels.htm or www.4cityhotels.com
Conference + Full Access Save £200 Save £100
to Conference Recordings* c £1798 + VAT c £1898 + VAT c £1998 + VAT
DIGITAL CONFERENCE ON CD ROM
Save £100 A digital version of the conference proceedings, including all
Conference Only
c £1399 + VAT c £1499 + VAT c £1499 + VAT presentations, is available to buy.
c I cannot attend the event, please send me the CD Rom
priced at £599 plus VAT
* Tick this Box if you Wish to Opt Out of Full Access to Conference Recordings (Reducing Price by £499) c
Recent digital conferences available - £599 plus VAT each
** Please select choice of workshop A c B c or C c
*** To qualify for discounts, payments must be received by the early bird registration deadline. Early booking discounts are not valid in conjunction c Compound Management
with any other offer. c Improving Solubility for Pharmaceuticals and Biologics
All above prices are subject to UK VAT at 17.5%. VAT Reg# GB 799 2259 67 c Polymorphism and Crystallisation
c Clinically Relevant Drug Transporters
Delegate Information c Pharmaceutical Co-Crystals 2010
c Amorphous Pharmaceutical Materials 2010
c Please send me conference materials indicated above.
DELEGATE cMr cMrs cMiss cMs cDr cOther c I have filled out credit card details opposite.
First Name For further information Please call: 0207 368 9300
or email: knowledgebank@iqpc.co.uk.
Family Name To search IQPC’s archived conference documentation
visit:www.iqpcknowledgebank.com
Position
Email
Organisation TERMS CONDITIONS
Please read the information listed below as each booking is subject to IQPC Ltd
Address standard terms and conditions.
Payment terms: Upon completion and return of the registration form, full
Tel Fax payment is required no later than 5 business days from the date of invoice.
Payment of invoices by means other than by credit card, or purchase order (UK
Approving Manager Plc and UK government bodies only) will be subject to a £49 (plus VAT) per delegate
processing fee. Payment must be received prior to the conference date. We reserve
the right to refuse admission to the conference if payment has not been received.
Signature
IQPC Cancellation, Postponement and Substitution Policy: You
I agree to IQPC’s cancellation and payment terms may substitute delegates at any time by providing reasonable advance notice to
IQPC. For any cancellations received in writing not less than eight (8) days prior
to the conference, you will receive a 90% credit to be used at another IQPC
conference which must occur within one year from the date of issuance of such
credit. An administration fee of 10% of the contract fee will be retained by IQPC
for all permitted cancellations. No credit will be issued for any cancellations
Payment Methods Total price for your organisation (Add total of all individuals attending): occurring within seven (7) days (inclusive) of the conference. In the event that IQPC
cancels an event for any reason, you will receive a credit for 100% of the contract
fee paid. You may use this credit for another IQPC event to be mutually agreed
Card Type: VISAc c c M/C AMEX
with IQPC, which must occur within one year from the date of cancellation. In the
event that IQPC postpones an event for any reason and the delegate is unable or
unwilling to attend in on the rescheduled date, you will receive a credit for 100%
Card Number: cccccccccccccccc of the contract fee paid. You may use this credit for another IQPC event to be
mutually agreed with IQPC, which must occur within one year from the date of
postponement. Except as specified above, no credits will be issued for cancellations.
There are no refunds given under any circumstances. IQPC is not responsible
Exp. Date: cccc cccc Sec:
for any loss or damage as a result of a substitution, alteration or cancellation/
postponement of an event. IQPC shall assume no liability whatsoever in the event
this conference is cancelled, rescheduled or postponed due to a fortuitous event,
Act of God, unforeseen occurrence or any other event that renders performance
Name On Card: Signature: of this conference impracticable, illegal or impossible. For purposes of this clause,
a fortuitous event shall include, but not be limited to: war, fire, labour strike,
extreme weather or other emergency. Please note that while speakers and topics
Billing Address (if different from above):
Conference Code: 19003.001
were confirmed at the time of publishing, circumstances beyond the control
of the organizers may necessitate substitutions, alterations or cancellations of
the speakers and/or topics. As such, IQPC reserves the right to alter or modify
the advertised speakers and/or topics if necessary without any liability to you
City/County/Postcode whatsoever. Any substitutions or alterations will be updated on our web page as
soon as possible.
Cheque enclosed for: £ Discounts: All ‘Early Bird’ Discounts require payment at time of registration
and before the cut-off date in order to receive any discount. Any discounts offered
(Made payable to IQPC Ltd.) whether by IQPC (including team discounts) must also require payment at the time
By Direct Transfer: IQPC Bank Details: HSBC Bank, 67 George Street, Richmond, Surrey, TW9 1HG of registration. All discount offers cannot be combined with any other offer.
Account No: 51304143 Account Name: IQPC Ltd IBAN No: GB59 MIDL 4038 1851 3041 43 Data protection: Personal data is gathered in accordance with the Data
Sort Code: 40 38 18 Swift Code: MIDLGB2112V Ref: Please include name of the attendee(s) and the conference code 19003.001 Protection Act 1998. Your details may be passed to other companies who wish to
communicate with you offers related to your business activities. If you do not wish
to receive these offers, please tick the box below.
Please do not pass my information to any third party
c
PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE
©IQPC Ltd. 2010 UK VAT registration no. GB 799 2259 67